Quick Takeaways
- Lind Global Fund III LP filed SCHEDULE 13G for Silexion Therapeutics Corp Ordinary shares, par value $0.0135 per share (SLXN).
- Disclosed ownership: 9.9%.
- Date of event: 12 Sep 2025.
Lind Global Fund III LP - 12 Sep 2025 SCHEDULE 13G Report for Silexion Therapeutics Corp Ordinary shares, par value $0.0135 per share (SLXN)
- Filing Manager
- Lind Global Fund III LP
- Reporting Manager
- Lind Global Fund III LP
- Symbol
- SLXN
- Shares outstanding
- 2,263,131 shares
- Disclosed Ownership
- 224,050 shares
- Ownership
- 9.9%
- Form type
- SCHEDULE 13G
- Filing time
- 18 Sep 2025, 17:47:12 UTC
- Date of event
- 12 Sep 2025
- Next filing
- 14 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Lind Global Fund III LP disclosed 9.9% ownership in Silexion Therapeutics Corp Ordinary shares, par value $0.0135 per share (SLXN) on 12 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 18 Sep 2025, 17:47.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Lind Global Fund III LP | 9.9% | 224,050 | 224,050 | 0 | By: Lind Global Partners III LLC, its General Partner, By: /s/ Jeff Easton | Jeff Easton, Managing Member | |
| Lind Global Partners III LLC | 9.9% | 224,050 | 224,050 | 0 | By: Lind Global Partners III LLC, its General Partner, By: /s/ Jeff Easton | Jeff Easton, Managing Member | |
| EASTON JEFF | 9.9% | 224,050 | 224,050 | 0 | /s/ Jeff Easton | Jeff Easton |